With billions at stake, will biosims finally make a mark in the U.S. in 2017?
28 December 2016
Biosimilars have already taken hold in Europe, with Celltrion's Remicade copy, for one, wreaking havoc on the branded med's sales. Whether they'll finally make their mark in the U.S., though, remains to be seen—and 2017 could be the year we find out.
2016's cybersecurity risks raise questions about future interconnectivity
28 December 2016
2016 saw a couple of incidents that spotlighted the vulnerability of medical devices to hacking and cyberattacks. But while cybersecurity flaws—such as those that could allow hackers to overdose a diabetic on insulin—can affect medical devices in their current form, the trend of increasing connectivity in med tech will only create more opportunities for unauthorized actors to exploit.
Artificial intelligence ramped up in 2016, but has to prove its utility in 2017
27 December 2016
According to MedyMatch Chief Financial Officer Michael Rosenberg, 2016 was a banner year for artificial intelligence. How does he know? “Even my mother knows what it is now. It’s going mainstream.”
The top trends for med tech in 2017
27 December 2016
If 2016 was the year that med tech players bet big on emerging and exciting technologies, 2017 will be the year to buckle down, generate evidence of the new tech’s utility and find its niche in the industry. This year, numerous companies made moves in artificial intelligence, while GlaxoSmithKline and Verily threw down $715 million on a bioelectronics-oriented joint venture. Meanwhile, M&A and venture capital funding took a dip, and a few events highlighted current and future cybersecurity risks that may materialize as med tech becomes more connected.
Biotech IPO market slowdown—will it continue into 2017?
26 December 2016
This year will not go down as a classic for biotech IPOs; in fact, it’s been pretty dismal, with a report by Renaissance Capital out in the summer showing that almost all of the biotech IPOs that priced since the first quarter have broken issue, and were trading below their offer price.
As the dust settles on Cures, what will it mean for biopharma R&D?
23 December 2016
At almost 1,000 pages, the 21st Century Cures Act is quite literally a weighty piece of legislation that will have far-reaching consequences for pharma in 2017 and beyond.
The top biopharma trends of 2016, and looking ahead to 2017
23 December 2016
It’s the time of year for editors to look ahead and attempt to predict, based on the patterns of the past 12 months, what the next trip around the sun will bring.
Biosimilars Supporting Contract Manufacturers’ Growth
21 December 2016
Biosimilars are finally becoming mainstream global products, including more than 20 having received approval in the European Union. The United States has been a prominent country lagging behind in its biosimilars approvals, with four approved by FDA. But many more approvals are on the way. This article examines impacts biosimilars are having on the biopharmaceutical contract manufacturing organization (CMO) sector. This includes capacity needs, and where biosimilars are requiring improved services, particularly related to biosimilarity testing and bioassays.
PWC “Top health industry issues of 2017: A year of uncertainty and opportunity”.
21 December 2016
PwC Health Research Institute’s annual report highlights the forces that are expected to have the most impact on the healthcare industry in the coming year.
Patient connections will be key in pharma's year of 'opportunity,' PwC says
21 December 2016
PwC's pharma and healthcare predictions for 2017 are out. And though, yes, next year may be "a year of uncertainty" with U.S. President-elect Donald Trump set to step in, it's also a year of "opportunity," the consultancy says.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Russia has expanded the mandatory health insurance program for 2024-2026
29 March 2024
Russian scientists have developed new TB vaccines for both injection and nasal administration.
29 March 2024
The overall mortality rate of the population in Russia decreased by 7% in 2023
28 March 2024
Russia to collaborate with Hungary and Serbia in nuclear medicine
28 March 2024